Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma

Table 4

Multivariate analyses of combination of AAPR and established staging systems in the validation cohorts.

Prognostic factor	Validation cohort 1						Validation cohort 2
	Overall survival			Disease-free survival			Overall survival
	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value	Hazard ratio	95% CI	P value
AJCC	2.329	1.701–3.189	<0.001	1.784	1.407–2.262	<0.001	1.474	1.322–1.643	<0.001
AAPR (>0.68/0.23–0.68/<0.23)	1.926	1.060–3.500	0.031	1.577	1.010–2.460	0.045	2.185	1.780–2.683	<0.001
BCLC	1.721	1.288–2.301	<0.001	1.567	1.246–1.971	<0.001	2.119	1.771–2.535	<0.001
AAPR (>0.68/0.23–0.68/<0.23)	2.505	1.358–4.620	0.003	1.496	1.046–2.140	0.027	1.791	1.448–2.216	<0.001
CLIP	1.641	1.220–2.207	0.001	1.398	1.109–1.764	0.005	1.678	1.539–1.829	<0.001
AAPR (>0.68/0.23–0.68/<0.23)	2.787	1.544–5.031	0.001	1.682	1.190–2.378	0.003	1.518	1.225–1.881	<0.001
CUPI	3.498	1.553–7.878	0.003	2.810	1.365–5.786	0.005	2.238	1.866–2.685	<0.001
AAPR (>0.68/0.23–0.68/<0.23)	2.500	1.327–4.709	0.005	1.622	1.135–2.318	0.008	1.306	1.024–2.685	0.0312
JIS	2.221	1.660–2.972	<0.001	1.664	1.343–2.063	<0.001	1.816	1.599–2.062	<0.001
AAPR (>0.68/0.23–0.68/<0.23)	2.144	1.173–3.921	0.013	1.449	1.013–2.073	0.042	1.644	1.325–2.040	<0.001